SG11201901925RA - Methods of treating acute kidney injury - Google Patents
Methods of treating acute kidney injuryInfo
- Publication number
- SG11201901925RA SG11201901925RA SG11201901925RA SG11201901925RA SG11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- english
- pct
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111101111111111111111111001111111111111111111111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/067857 Al 12 April 2018 (12.04.2018) WIP0 1 PCT (51) International Patent Classification: A61K 31/192 (2006.01) A61K 31/4439 (2006.01) Published: A61K 31/4192 (2006.01) A61P 13/12 (2006.01) — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/055400 amendments (Rule 48.2(h)) (22) International Filing Date: 05 October 2017 (05.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/404,390 05 October 2016 (05.10.2016) US (71) Applicant: MITOBRIDGE, INC. [US/US]; 1030 Massa- chusetts Avenue, Suite 200, Cambridge, MA 02138 (US). (72) Inventors: LAGU, Bharat; 21 Lexington Drive, Acton, MA 01720 (US). PATANE, Michael; 6 Westwind Road, Andover, MA 01810 (US). TOZZO, Effie; 898 Massa- chusetts Avenue, Lexington, MA 02420 (US). TRZASKA, Scott; 8 Renzi Road, Raritan, NJ 08869 (US). Agent: DAVIS, Steven, G. et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US). (74) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) — Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) under Rule 4.17: ,- 1 Declarations ..! — IN in — GC IN as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) 0 --.... 00 1-1 (54) Title: METHODS OF TREATING ACUTE KIDNEY INJURY 0 ei (57) : The present invention is directed to methods of treating a human patient with acute kidney injury.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901925RA true SG11201901925RA (en) | 2019-04-29 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901925RA SG11201901925RA (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20210283116A1 (en) |
| EP (1) | EP3522880B1 (en) |
| JP (1) | JP7065839B2 (en) |
| KR (1) | KR20190062502A (en) |
| CN (1) | CN109789117B (en) |
| AU (1) | AU2017340760B2 (en) |
| BR (1) | BR112019005539A2 (en) |
| CA (1) | CA3036723A1 (en) |
| CO (1) | CO2019004561A2 (en) |
| CY (1) | CY1124759T1 (en) |
| DK (1) | DK3522880T3 (en) |
| ES (1) | ES2859487T3 (en) |
| HR (1) | HRP20210294T1 (en) |
| HU (1) | HUE053557T2 (en) |
| IL (1) | IL265749A (en) |
| JO (1) | JOP20190056B1 (en) |
| LT (1) | LT3522880T (en) |
| MA (1) | MA46459B1 (en) |
| MD (1) | MD3522880T2 (en) |
| MX (1) | MX2019003949A (en) |
| MY (1) | MY192385A (en) |
| PH (1) | PH12019500725A1 (en) |
| PL (1) | PL3522880T3 (en) |
| PT (1) | PT3522880T (en) |
| RS (1) | RS61573B1 (en) |
| RU (1) | RU2753607C2 (en) |
| SG (1) | SG11201901925RA (en) |
| SI (1) | SI3522880T1 (en) |
| SM (1) | SMT202100111T1 (en) |
| TW (1) | TWI778982B (en) |
| UA (1) | UA124019C2 (en) |
| WO (1) | WO2018067857A1 (en) |
| ZA (1) | ZA201901743B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037371B1 (en) | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109071459B (en) * | 2016-04-13 | 2022-08-16 | 米托布里奇公司 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| LT3523283T (en) | 2016-10-05 | 2021-07-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| KR20220042150A (en) * | 2019-07-19 | 2022-04-04 | 비포르 (인터내셔날) 아게 | Ferroportin inhibitors for use in the prevention and treatment of kidney damage |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115813901B (en) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | Application of 3-phenyl glutaric acid derivative small molecule in preparation of medicament for preventing and treating cisplatin-induced acute kidney injury |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2539403C (en) | 2003-09-19 | 2013-11-19 | Janssen Pharmaceutica N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| ZA200610650B (en) * | 2004-05-25 | 2009-04-29 | Metabolex Inc | Substituted triazoles as modulators of PPAR and methods of their preparation |
| RU2320341C1 (en) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Preparation for treating acute obstruction of the upper urinary tract |
| KR20090071829A (en) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | Pharmaceutical composition for the treatment and prevention of kidney disease |
| CA2740874C (en) | 2008-10-17 | 2018-02-27 | Metabolex, Inc. | Use of ppar.gamma.agonists to reduce small dense ldl particles |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| CA2901922A1 (en) | 2013-03-08 | 2014-09-12 | Abbvie Inc. | Methods of treating acute kidney injury |
| CA2908695A1 (en) * | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
| EP2862574A1 (en) | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| CN105917229B (en) * | 2013-12-03 | 2019-04-26 | 阿斯图特医药公司 | Methods and compositions for the diagnosis and prognosis of renal injury and renal failure |
| WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| WO2016057658A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EA037371B1 (en) * | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
-
2017
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/en active
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/en unknown
- 2017-10-05 TW TW106134387A patent/TWI778982B/en active
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/en active
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/en unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/en unknown
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/en unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en active Application Filing
- 2017-10-05 ES ES17787773T patent/ES2859487T3/en active Active
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en active Active
- 2017-10-05 RS RS20210203A patent/RS61573B1/en unknown
- 2017-10-05 PT PT177877735T patent/PT3522880T/en unknown
- 2017-10-05 MA MA46459A patent/MA46459B1/en unknown
- 2017-10-05 SI SI201730653T patent/SI3522880T1/en unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/en active Active
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/en active Active
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/en not_active Ceased
- 2017-10-05 BR BR112019005539A patent/BR112019005539A2/en not_active Application Discontinuation
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/en unknown
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/en active
- 2017-10-05 MX MX2019003949A patent/MX2019003949A/en unknown
- 2017-10-05 UA UAA201904011A patent/UA124019C2/en unknown
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/en unknown
-
2021
- 2021-02-22 HR HRP20210294TT patent/HRP20210294T1/en unknown
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease |